Bayer Raises FY Group Sales Outlook; Allocates Extra EUR 1.2 Bln For Glyphosate Litigation
I'm PortAI, I can summarize articles.
Bayer AG has raised its full-year sales outlook to between 46 billion and 48 billion euros, up from 45 to 47 billion euros, following strong performance in its Pharmaceuticals division. The company allocated an additional 1.2 billion euros for glyphosate litigation, contributing to a total of 1.7 billion euros. Core earnings per share are now projected at 4.80 to 5.30 euros, an increase from the previous forecast. Bayer anticipates currency effects to reduce sales by around 2 billion euros and EBITDA by approximately 500 million euros. Detailed Q2 results will be published on August 6, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments